Ritter Pharmaceuticals
Los Angeles
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. We are discovering a new frontier in human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into safe and effective applications that can have a meaningful impact on a patient’s health. Our pipeline of novel microbiome modulators selectively increase the growth of beneficial bacteria in the colonic ecosystem and create a meaningful impact on a patient’s health. Our first therapy, RP-G28, is currently under development for the treatment of lactose intolerance and has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. RP-G28 has been studied in a Phase 2 clinical trial and is a first-in-class compound.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $25.7M
- Funding stage: M&A
- Last round: Post-IPO Equity (Dec 2015)
- Ticker: nasdaq:RTTR
- Website: ritterpharma.com
- Phone: +1 310-203-1000
Industries & Categories
Biotechnology, Clinical Trials, Health Diagnostics, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ritter-pharmaceuticals-1058044 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.